Brendan Larder

13.5k citations

134 papers · 11.2k indexed · 4 hit papers · h-index 59

Virology top 0.02%
Infectious Diseases top 0.05%
Epidemiology top 1%
Molecular Biology top 5%
Hepatology top 1%

Co-authors: Sharon D. Kemp G. Darby Paul Kellam Stuart Bloor P. Richard Harrigan Kurt Hertogs Charles A. Boucher D. J. M. Purifoy
Topics: HIV Research and Treatment (116 papers)HIV/AIDS drug development and treatment (115 papers)HIV/AIDS Research and Interventions (76 papers)
Cited by: Virology Infectious Diseases Hepatology
Journals: Nature Science Proceedings of the National Academy of Sciences
Partner nations: United Kingdom United States Netherlands

In The Last Decade

Brendan Larder

133 papers receiving 10.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)

1989 980 citations Brendan Larder, Sharon D. Kemp profile →
Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptase

1991 587 citations Paul Kellam, Sharon D. Kemp et al. profile →
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

1993 523 citations Sharon D. Kemp, Brendan Larder et al. profile →
Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy

1995 518 citations Brendan Larder, Sharon D. Kemp et al. profile →

Peers

Countries citing papers authored by Brendan Larder

Since Specialization

Citations

This map shows the geographic impact of Brendan Larder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brendan Larder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brendan Larder more than expected).

Fields of papers citing papers by Brendan Larder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brendan Larder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brendan Larder. The network helps show where Brendan Larder may publish in the future.

Co-authorship network of co-authors of Brendan Larder

This figure shows the co-authorship network connecting the top 25 collaborators of Brendan Larder. A scholar is included among the top collaborators of Brendan Larder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brendan Larder. Brendan Larder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Evaluation of the Potential Utility of Computational Modeling as an HIV Treatment Selection Tool by Physicians with Considerable HIV Experience 2011 ·AIDS Patient Care and STDs ·Brendan Larder,Andrew Revell,JoAnn M. Mican,Brian K. Agan,Marianne Harris,Carlo Torti,Ilaria Izzo,Julia A. Metcalf,(unknown),Vincent C. Marconi,Dechao Wang,Dan Coe,Brian Gazzard,Julio Montaner,H. Clifford Lane	16
2	The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool 2011 ·AIDS ·Andrew Revell,Dechao Wang,Mark Boyd,Sean Emery,Anton Pozniak,(unknown),Richard Harrigan,Julio Montaner,Clifford Lane,Brendan Larder	20
3	Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings 2010 ·Journal of Antimicrobial Chemotherapy ·Andrew Revell,(unknown),Richard Harrigan,Raph L Hamers,Amj Wensing,(unknown),Mark Nelson,Anna María Geretti,Brendan Larder	23
4	Progress in Basic and Clinical Research on HIV Resistance: Report on the XVIII International HIV Drug Resistance Workshop 2009 ·Antiviral Therapy ·(unknown),Charles A. Boucher,John W. Mellors,Brendan Larder,Douglas D. Richman	1
5	Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV drug access initiative – Uganda 2003 ·AIDS ·Paul J. Weidle,Robert Downing,(unknown),Raymond Mwebaze,(unknown),Samuel S. Malamba,Richard Respess,Kurt Hertogs,Brendan Larder,(unknown),Jonathan Mermin,Badara Samb,Eve Lackritz	31
6	Enhanced Prediction of Lopinavir Resistance from Genotype by Use of Artificial Neural Networks 2003 ·The Journal of Infectious Diseases ·Dechao Wang,Brendan Larder	78
7	Broad Nucleoside‐Analogue Resistance Implications for Human Immunodeficiency Virus Type 1 Reverse‐Transcriptase Mutations at Codons 44 and 118 2002 ·The Journal of Infectious Diseases ·Laura Romanó,Giulietta Venturi,Stuart Bloor,Richard Harrigan,Brendan Larder,(unknown),Maurizio Zazzi	44
8	Baseline Antiretroviral Drug Susceptibility Influences Treatment Response in Patients Receiving Saquinavir-Enhancing Therapy 2001 ·HIV Clinical Trials ·(unknown),Don Smith,Brendan Larder,Matthew Law,Chris Birch	9
9	Impact of HIV Type 1 Drug Resistance Mutations and Phenotypic Resistance Profile on Virologic Response to Salvage Therapy 2001 ·AIDS Research and Human Retroviruses ·Lisa Ross,Qiming Liao,Haitao Gao,Sissi V. Pham,Jerry M. Tolson,Kurt Hertogs,Brendan Larder,Michael S. Saag	12
10	High Prevalence of Genotypic and Phenotypic HIV-1 Drug-Resistant Strains Among Patients Receiving Antiretroviral Therapy in Abidjan, Côte d'Ivoire 2001 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·(unknown),Rachanee Cheingsong,Thierry H. Roels,Chantal Maurice,Gaston Djomand,Werner Verbiest,Kurt Hertogs,Brendan Larder,Ben Monga,Martine Peeters,Serge Eholié,(unknown),(unknown),Richard Respess,Stefan Z. Wiktor,Terence Chorba,John N. Nkengasong	82
11	World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing 2001 ·AIDS ·P. Richard Harrigan,Joan Montaner,Scott A. Wegner,Werner Verbiest,Veronica Miller,Robin Wood,Brendan Larder	95
12	Phenotypic Cross-Resistance to Nelfinavir: The Role of Prior Antiretroviral Therapy and the Number of Mutations in the Protease Gene 2001 ·AIDS Research and Human Retroviruses ·Fernando Dronda,José L. Casado,Santiago Moreno,Kurt Hertogs,Isabel García-Arata,Antonio Antela,Maria Jesús Pérez‐Elías,Lı́dia Ruiz,Brendan Larder	18
13	Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples 2000 ·AIDS ·Brendan Larder,Kurt Hertogs,Stuart Bloor,(unknown),(unknown),(unknown),William W. Freimuth,(unknown)	112
14	Evidence of a Source of HIV Type 1 within the Central Nervous System by Ultraintensive Sampling of Cerebrospinal Fluid and Plasma 2000 ·AIDS Research and Human Retroviruses ·David W. Haas,(unknown),Benjamin Johnson,(unknown),Paul Spearman,G. Wilkinson,Courtney V. Fletcher,Susan A. Fiscus,Stephen Raffanti,(unknown),(unknown),Janet Nicotera,Dennis E. Schmidt,Ronald E. Shoup,Robert E. Kates,Robert M. Lloyd,Brendan Larder	43
15	The Rabbit Study: Ritonavir and Saquinavir in Combination in Saquinavir-Experienced and Previously Untreated Patients 1999 ·AIDS Research and Human Retroviruses ·Duncan Churchill,Alexander S. Pym,S. Galpin,Russell B. Foxall,(unknown),John R. Clarke,Steve Kaye,Stuart Bloor,Brendan Larder,(unknown),Eugene Sun,Abdel G. Babiker,D.J. Back,Jonathan Weber	5
16	Dual Resistance to Zidovudine and Lamivudine in Patients Treated with Zidovudine‐Lamivudine Combination Therapy: Association with Therapy Failure 1998 ·The Journal of Infectious Diseases ·Veronica Miller,Andrew Phillips,(unknown),Schlomo Staszewski,Rudi Pauwels,Kurt Hertogs,Marie‐Pierre de Béthune,Sharon D. Kemp,Stuart Bloor,P. Richard Harrigan,Brendan Larder	74
17	11 Inhibitors of HIV Reverse Transcriptase as Antiviral Agents and Drug Resistance 1993 ·Cold Spring Harbor Monograph Archive ·Brendan Larder	38
18	Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing 1993 ·Nature ·Brendan Larder,Arinder Kohli,Paul Kellam,Sharon D. Kemp,Mel N. Kronick,(unknown)	164
19	The clinical significance of antiviral drug resistance 1992 ·Research in Virology ·G. Darby,Brendan Larder	8
20	Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy 1990 ·The Lancet ·Charles A. Boucher,J Lange,Jaap Goudsmit,Jan W. Mulder,M Tersmette,R. E. Y. de Goede,Paul Kellam,G. Darby,Brendan Larder	148

About Brendan Larder

Brendan Larder is a scholar working on Virology, Infectious Diseases and Hepatology, having authored 134 papers that have together received 11.2k indexed citations. Recurring topics across this work include HIV Research and Treatment (116 papers), HIV/AIDS drug development and treatment (115 papers) and HIV/AIDS Research and Interventions (76 papers). The work is most often cited by research in Virology (9.3k citations), Infectious Diseases (9.3k citations) and Hepatology (679 citations). Brendan Larder has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Sharon D. Kemp, G. Darby, Paul Kellam, Stuart Bloor, P. Richard Harrigan, Kurt Hertogs, Charles A. Boucher, D. J. M. Purifoy, Margaret Tisdale and Veronica Miller. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact